目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T62509 | |||
Antitumor agent-74 是一种喹唑啉衍生物,是一种抗肿瘤剂。Antitumor agent-74 与区域同分异构体 Antitumor agent-75 (compound 14 da) (mriBIQ 13da/14da) 联合使用表现出更强的肿瘤抑制效果。其中 mriBIQ 13da/14da 能够抑制 DNA 合成,将细胞周期阻滞在 S 期,并诱导线粒体凋亡。 | |||
T74327 | |||
Antitumor agent-41 (compound N-12),一种具有卓越抗迁移及抗侵袭能力的抗肿瘤剂。通过坏死和炎症通路实现其抗肿瘤作用。 | |||
T60421 | |||
Antitumor agent-68 是一种有效的微管蛋白抑制剂,具有良好的抗肿瘤活性,对宫颈癌细胞系 HeLa 和乳腺癌细胞系 MCF-7 细胞的IC50值分别为 3.6 和 3.8 μM。Antitumor agent-68 以剂量依赖的方式表现出良好的 ROS 和DPPH 自由基的清除活性。 | |||
T61656 | |||
Antitumor agent-53 is a potent compound that effectively inhibits tumor growth. It achieves this by inducing cell cycle arrest at the G2/M phase and promoting apoptosis in HGC-27 cells through the inhibition of the PI3K/AKT pathway. Furthermore, Antitumor agent-53 holds promise for further research in the treatment of gastrointestinal tumors [1]. | |||
T83006 | |||
Antitumor agent-29为新型肝细胞靶向抗肿瘤前体,表现出优异抗肿瘤活性及低毒性副作用。 | |||
T72552 | |||
Antitumor agent-88 表现出有效的抗有丝分裂活性并使细胞停滞在 G2/M 期。Antitumor agent-88 扰乱表达 CYP1A1 的乳腺癌细胞中的微管和细胞骨架。Antitumor agent-88 也是 CYP1A1的竞争性抑制剂 (Ki: 1.4 μM)。 | |||
T64111 | |||
Antitumor agent-76 是一种水溶性的、口服具有活力的、快速释放的 Triptolide 前药,表现出抗癌效果。 | |||
T72551 | |||
Antitumor agent-87为一种有效抗肿瘤化合物,对CYP1A1具有高亲和性(Ki值0.23 µM),表现出抗增殖活性并能诱导细胞周期在G2/M期停滞,进而展现抗肿瘤活性。 | |||
T72560 | |||
Antitumor agent-81 (化合物 5 a) 是一种低细胞毒性的 P62-RNF168激动剂,能促进 P62与RNF168的相互作用。Antitumor agent-81 诱导RNF168介导的H2A 泛素化减少,并损害同源重组介导的 DNA 修复。Antitumor agent-81 还能以剂量依赖的方式抑制小鼠异种移植肿瘤的生长。 | |||
T83009 | |||
Antitumor agent-107(化合物5h)是一款抗癌剂,对白血病细胞系展现出显著的抑制作用(GI50=0.32-1.34 μM)。该化合物对其他多种人类癌细胞系亦显示出了抗肿瘤活性(GI50值介于0.35-9.43 μM之间)。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-06983 | IFN gamma Protein, Human, Recombinant (E. coli) | Human | E. coli | ||
IFN gamma, also known as IFNG, is a secreted protein that belongs to the type II interferon family. IFN gamma is produced predominantly by natural killer and natural killer T cells as part of the innate immune response, and by CD4 and CD8 cytotoxic T lymphocyte effector T cells once antigen-specific immunity develops. IFN gamma has antiviral, immunoregulatory, and anti-tumor properties. IFNG, in addition to having antiviral activity, has important immunoregulatory functions, it is a potent activator of macrophages and has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. The IFNG monomer consists of a core of six α-helices and an extended unfolded sequence in the C-terminal region. IFN gamma is critical for innate and adaptive immunity against viral and intracellular bacterial infections and tumor control. Aberrant IFN gamma expression is associated with some autoinflammatory and autoimmune diseases. The importance of IFN gamma in the immune system stems in part from its ability to inhibit viral replication directly, and most importantly from its immunostimulatory and immunomodulatory effects. IFNG also promotes NK cell activity.
|
|||||
TMPH-03055 | Ribonuclease mitogillin Protein, Neosartorya fumigata, Recombinant (His & Myc & SUMO) | Neosartorya fumigata | E. coli | ||
This purine-specific ribonuclease cleaves 28S RNA in eukaryotic ribosomes, inhibits protein synthesis, and shows antitumor activity.
|
|||||
TMPK-01520 | HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01417 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01519 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPH-00131 | Ribonuclease mitogillin Protein, Aspergillus restrictus, Recombinant (His & Myc) | Aspergillus restrictus | E. coli | ||
This purine-specific ribonuclease cleaves 28S RNA in eukaryotic ribosomes, inhibits protein synthesis, and shows antitumor activity. Ribonuclease mitogillin Protein, Aspergillus restrictus, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 23.9 kDa and the accession number is P67876.
|
|||||
TMPK-01477 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPJ-00008 | CXCL10 Protein, Human, Recombinant (hFc & His) | Human | HEK293 Cells | ||
Human C-X-C Motif Chemokine Ligand 10 (CXCL10) is a non-ELR chemokine secreted by various cell types, such as monocytes, endothelial cells and fibroblasts, in response to IFN-γ. CXCL10 functions via chemokine receptor CXCR3. CXCL10 has been attributed to several roles, such as chemoattraction for activated T-lymphocytes, inhibition of angiogenesis, and antitumor activity.
|
|||||
TMPK-01484 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01478 | HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01436 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01521 | HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPH-00373 | IFN gamma Protein, Chicken, Recombinant (GST) | Chicken | E. coli | ||
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. IFN gamma Protein, Chicken, Recombinant (GST) is expressed in E. coli expression system with N-GST tag. The predicted molecular weight is 43.7 kDa and the accession number is P49708.
|
|||||
TMPK-01482 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-00126 | CLEC4A Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy. CLEC4A Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 46.7 kDa and the accession number is Q9UMR7-1.
|
|||||
TMPK-00127 | CLEC4A Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy. CLEC4A Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 46.3 kDa and the accession number is Q9QZ15.
|
|||||
TMPK-01483 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01515 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-00248 | TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 19.4 kDa and the accession number is Q9UBN6.
|
|||||
TMPH-02451 | IFN gamma Protein, Marmota monax, Recombinant (His) | Marmota monax | P. pastoris (Yeast) | ||
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. IFN gamma Protein, Marmota monax, Recombinant (His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 18.6 kDa and the accession number is O35735.
|
|||||
TMPK-00249 | TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 19.4 kDa and the accession number is Q9UBN6.
|
|||||
TMPJ-00076 | IL-28B Protein, Human, Recombinant | Human | HEK293 Cells | ||
Interleukin-28B, also known as Cytokine Zcyto22, Interferon lambda-3, Interferon lambda-4, IFNL3, IFNL4, ZCYTO22 and IL28B, is a secreted cytokine which belongs to the IL-28/IL-29 family. IL-28 has also been shown to play a role in the adaptive immune response. IL28B has immunomodulatory activity and up-regulates MHC class I antigen expression. IL28B displays potent antiviral activity and antitumor activity. In addition, IL28B is a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand/receptor complex seems to signal through the Jak-STAT pathway.
|
|||||
TMPH-00775 | IFN gamma Protein, Goat, Recombinant (His & Myc) | Goat | E. coli | ||
Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading. Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference. Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL. Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation.
|
|||||
TMPH-02524 | Arginase-1/ARG1 Protein, Mouse, Recombinant (His) | Mouse | P. pastoris (Yeast) | ||
Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys.; Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the available intracellular substrate arginine. Arginine metabolism is a critical regulator of innate and adaptive immune responses. Involved in an antimicrobial effector pathway in polymorphonuclear granulocytes (PMN). Upon PMN cell death is liberated from the phagolysosome and depletes arginine in the microenvironment leading to suppressed T cell and natural killer (NK) cell proliferation and cytokine secretion. In group 2 innate lymphoid cells (ILC2s) promotes acute type 2 inflammation in the lung and is involved in optimal ILC2 proliferation but not survival. Plays a role in the immune response of alternatively activated or M2 macrophages in processes such as wound healing and tissue regeneration, immune defense against multicellular pathogens and parasites, and immune suppression and allergic inflammation; the regulatory outcome seems to be organ specific. In tumor-infiltrating dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs) plays a role in suppression of T cell-mediated antitumor immunity.
|